Trevena Inc. (NASDAQ:TRVN) SVP Carrie L. Bourdow acquired 4,000 shares of the firm’s stock in a transaction on Wednesday, November 9th. The shares were bought at an average price of $4.34 per share, for a total transaction of $17,360.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Trevena Inc. (NASDAQ:TRVN) opened at 6.09 on Monday. The stock’s market cap is $318.71 million. Trevena Inc. has a 12-month low of $3.76 and a 12-month high of $13.02. The firm’s 50-day moving average price is $5.80 and its 200-day moving average price is $6.65.

Trevena (NASDAQ:TRVN) last released its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.40) by $0.17. Trevena had a negative return on equity of 66.50% and a negative net margin of 841.00%. On average, analysts forecast that Trevena Inc. will post ($1.91) EPS for the current fiscal year.

A number of research analysts have recently commented on TRVN shares. Cowen and Company reaffirmed a “buy” rating and set a $13.00 target price on shares of Trevena in a research note on Friday, August 5th. Zacks Investment Research raised Trevena from a “sell” rating to a “hold” rating in a research note on Thursday, November 3rd. Brean Capital set a $14.00 target price on Trevena and gave the company a “buy” rating in a research note on Tuesday, October 25th. FBR & Co reaffirmed a “buy” rating and set a $13.00 target price on shares of Trevena in a research note on Thursday, August 4th. Finally, Wedbush reaffirmed an “outperform” rating and set a $16.00 target price on shares of Trevena in a research note on Thursday, November 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $14.30.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wells Fargo & Company MN raised its stake in Trevena by 51.9% in the third quarter. Wells Fargo & Company MN now owns 15,393 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 5,261 shares during the last quarter. National Planning Corp raised its stake in Trevena by 21.9% in the first quarter. National Planning Corp now owns 19,452 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 3,500 shares during the last quarter. Alliancebernstein L.P. purchased a new stake in Trevena during the second quarter valued at approximately $163,000. Highbridge Capital Management LLC purchased a new stake in Trevena during the second quarter valued at approximately $225,000. Finally, Metropolitan Life Insurance Co. NY raised its stake in Trevena by 54.6% in the second quarter. Metropolitan Life Insurance Co. NY now owns 35,964 shares of the biopharmaceutical company’s stock valued at $227,000 after buying an additional 12,694 shares during the last quarter. 75.52% of the stock is currently owned by institutional investors and hedge funds.

About Trevena

Trevena Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250.

5 Day Chart for NASDAQ:TRVN

Receive News & Stock Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related stocks with our FREE daily email newsletter.